Drugs / natural killer (NK) cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02890758 | May 2018 → Jun 2021 | Ewing sarcoma, Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +6 | Brenda Cooper, MD | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02809092 | Apr 2017 → Sep 2019 | acute myeloid leukemia | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 1/2 | NCT02849353 | Jul 2016 → Jul 2017 | ovarian cancer | Fuda Cancer Hospital, Guangzhou | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | natural killer (NK) cells | “combined therapy using cryosurgery and natural killer (NK) cells.” NCT02849353 ↗ |
| Modality | Cell therapy | “NK cell therapy was limited by small numbers of NK cells attainable through leukapheresis.” NCT02809092 ↗ |
| Route | Intravenous | “Three (3) times a week for 2 weeks, you will receive NK cells by vein over 30 minutes.” NCT02809092 ↗ |